[1] SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA,2016,315(8):801-810. [2] CAO M, WANG G Z, XIE J F.Immune dysregulation in sepsis: experiences, lessons and perspectives[J].Cell Death Discov,2023,9(1): 465. [3] GONZALEZ R, URBANO J, LOPEZ-HERCE J. Resuscitating the macro-vs. microcirculation in septic shock[J].Curr Opin Pediatr,2024,36(3): 274-281. [4] HERNA NDEZ G, OSPINA-TASCON G A, DAMIANI L P, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28- day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial[J].JAMA,2019, 321(7):654-664. [5] 陈豆豆,常青,章向成,等.连续性肾脏替代治疗对严重脓毒症患者肾功能及微循环的影响[J].广西医科大学学报, 2017, 34(6):851-854. [6] YOU B, ZHANG Y L, LUO G X, et al. Early application of continuous high-volume haemofiltration can reduce sepsis and improve the prognosis of patients with severe burns[J].Crit Care,2018,22(1):173. [7] IBA T, MAIER C L, HELMS J, et al. Managing sepsis and septic shock in an endothelial glycocalyx-friendly way: from the viewpoint of surviving sepsis campaign guidelines[J].Ann Intersive Care,2024,14(1):64. [8] LUPUF, KINASEWITZ G, DORMER K. The role of endo-thelial shear stress on haemodynamics , inflammation ,coagulation and glycocalyx during sepsis[J].J Cell Mol Med,2020, 24 (21): 12258-12271. [9] ZHANG L, FENG Y Y, FU P. Blood purification for sepsis: an overview[J].Precis Clin Med,2021, 4(1):45-55. [10] 徐飞方,朱义洪,薛细松.乌司他丁联合连续性血液净化治疗重症脓毒症的效果及对微循环指标、炎症指标及预后的影响[J].黑龙江医药科学,2024, 47(1):145-147. [11] STARRT-AKI INVESTIGATORS, CANADIAN CRITICAL CARE TRIALS GROUP, AUSTRALIAN AND NEW ZEALAND INTENSIVE CARE SOCIETY CLINICAL TRIALS GROUP, et al. Timing of initiation of renal-replacement therapy in acute kidney injury[J].N Engl J Med,2020,383(3): 240-251. [12] BARBAR S D, CLERE-JEHL R, BOURREDJEM A, et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis[J].N Engl J Med,2018,379(15):1431-1442. [13] 陈希, 万宏哲, 吴硕, 等.血液净化治疗启动时机及滤器选择对脓毒症患者短期预后的影响[J].中国血液净化,2023, 22(7):493-497. [14] 董云, 李辉, 韩晓瑞, 等.早期连续性血液净化治疗老年重症脓毒血症急性肾损伤的临床效果 [J].中国老年学杂志,2018,38(10):2423-2425. [15] 谢谦,生娣, 陈健, 等.脓毒症急性肾损伤患者血液净化时机选择对治疗期间微循环系统的影响研究[J].现代生物医学进展,2019,19(11):2129-2132. [16] 时建茹.不同血液净化模式对治疗脓毒症多脏器功能衰竭的疗效分析[J].医学临床研究, 2023, 31(12):50-53. [17] VILLA G, CHELAZZI C, MORETTINI E, et al. Organ dysfunction during continuous veno-venous high cut-off hemodialy-sis in patients with septic acute kidney injury: a prospec-tive observational study[J].PLoS One,2017,12:e0172039. [18] JOANNES-BOYAU O, HONORÉ PM, PEREZ P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial[J].Intensive Care Med,2013, 39(9): 1535-1546. [19] ATAN R, PECK L, PROWLE J, et al. A double-blind randomized controlled trial of high cutoff versus standard hemofiltration in critically ill patients with acute kidney injury[J].Crit Care Med,2018, 46(10):e988-e994. [20] CRUZ D N, ANTONELLI M, FUMAGALLI R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial[J].JAMA,2009, 301(23): 2445-2452. [21] LIVIGNI S, BERTOLINI G, ROSSI C, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial[J].BMJ Open,2014,4(1): e0035-e0036. [22] NIU D G, HUANG Q, YANG F, et al. Efficacy of coupled plasma filtration adsorption in treating patients with severe Intra-Abdominal infection: a retrospective study[J].J Laparoendosc Adv Surg Tech A,2019,29:905-908. [23] 俞国峰,吕铁,陆地,等.血液灌流对脓毒性休克高迁移率族蛋白 B-1 清除效果的研究 [J].中华医院感染学杂志, 2019, 29(1):23-26. [24] PICKKERS P, VASSILIOU T, LIGUTS V, et al. Sepsis management with a blood purification membrane: European experience[J].Blood Purif,2019, 47(3): 1-9. [25] ZHANG L, COVE M, NGUYEN B G, et al. Adsorptive hemofiltration for sepsis management: expert recommendations based on the Asia Pacific experience[J].Chin Med J (Engl),2021, 134(18): 2258-2260. [26] GUAN M J, WANG H, TANG X, et al. Continuous renal replacement therapy with adsorbing filter oxiris in acute kidney injury with septic shock: a retrospective observational study[J].Front Med (Lausanne),2022, 9: 789623. [27] BORG R, UGBOMA D, WALKER D M, e tal .Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: Aservice evaluation following a change in practice[J].Intensive Care Soc,2017,18(3):184-192. [28] 中华医学会肾脏病学分会专家组. 连续性肾脏替代治疗的抗凝管理指南[J].中华肾脏病杂志,2022,11(38):1016-1020. [29] HARADA N, OKAJIMA K, UCHIBA M. Dalteparin, a low molecular weight heparin, attenuates inflammatory re-sponses and reduces ischemia-reperfusion-induced liver injury in rats[J].Crit Care Med,2006, 34(7): 1883-1891. [30] 田培刚,刘贤英,程青红.低分子肝素对脓毒症大鼠肺血管内皮细胞的保护作用[J].中国老年学杂志,2019,39(7):1705-1708. [31] 李新,郑晓晶,崔巍,等.低分子肝素对脓毒症患者血浆TNF-α、IL-6及凝血功能的影响[J].疑难病杂志,2017,16(6):566-569.
2025, Vol. 42 
